INHIBIKASE THERAPEUTICS INC

Inhibikase Therapeutics’ shares fell 2.92% to $1.66, a steep 28% yearly drop, while peers like Zura Bio and Viemed Healthcare see mixed moves—stay ahead with the latest market insights.

IKT’s brief 3.95% rally masks a 22% monthly decline and weak fundamentals—read why the clinical‑stage kinase drug maker may still be a high‑risk play.

Inhibikase Therapeutics (IKT) sees a slight 0.3% dip amid sector-wide capital shifts, trading at $1.71 with a $228M market cap and 25% YTD decline.